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Abstract
Background Return of normal gastrointestinal (GI) function is a critical determinant of recovery after colorectal surgery. The 
aim of this meta-analysis was to evaluate whether perioperative intravenous (IV) lidocaine benefits return of gastrointestinal 
function after colorectal resection.
Methods A comprehensive search of Ovid Medline, PubMed, Embase, Cochrane library, and clinicaltrials.org was performed 
on 1st July 2018. A manual search of reference lists was also performed. Inclusion criteria were as follows: randomized con-
trolled trials (RCTs) of intravenous (IV) lidocaine administered perioperatively compared to placebo (0.9% saline infusion) 
as part of a multimodal perioperative analgesic regimen, human adults (> 16 years), and open or laparoscopic colorectal 
resectional surgery. Exclusion criteria: non-colorectal surgery, non-placebo comparator, children, non-general anaesthetic, 
and pharmacokinetic studies. The primary endpoint was time to first bowel movement. Secondary endpoints were time to 
first passage of flatus, time to toleration of diet, nausea and vomiting, ileus, pain scores, opioid analgesia consumption, and 
length of stay.
Results One hundred and ninety one studies were screened, with 9 RCTs meeting inclusion criteria (405 patients, four 
laparoscopic and five open surgery studies). IV lidocaine reduced time to first bowel movement compared to placebo [seven 
studies, 325 patients, mean weighted difference − 9.54 h, 95% CI 18.72–0.36, p = 0.04]. Ileus, pain scores, and length of stay 
were reduced with IV lidocaine compared with placebo.
Conclusions Perioperative IV lidocaine may improve recovery of gastrointestinal function after colorectal surgery. Large-
scale effectiveness studies to measure effect size and evaluate optimum dose/duration are warranted.
Keywords Intravenous lidocaine · Colorectal surgery · Ileus · Laparoscopic
Introduction
Colorectal resection causes an unavoidable cessation of nor-
mal gastrointestinal (GI) function in every patient; hence, the 
return of GI function is a critical determinant of recovery 
[1, 2]. Modern minimally invasive techniques and multi-
modal “enhanced recovery” programs have reduced the 
historically high prevalence of delayed return of GI func-
tion associated with open colorectal surgery [3, 4]. Despite 
this, return of GI function after colorectal resection can lag 
behind other aspects of recovery such as mobilization and 
pain control [5]. A prolonged delay in return of GI function 
(commonly known as postoperative ileus) is characterized 
by inability to resume normal diet, vomiting, abdominal 
distension, and absolute constipation, requires active sup-
portive management [intravenous (IV) fluids, anti-emetics, 
nasogastric intubation], and results in longer hospital stay 
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with a substantially poorer patient experience. Recovery of 
GI function is important to patients and surgeons alike and 
was identified as a key research focus in a recent research 
prioritization exercise undertaken jointly between patients 
and the Association of Coloproctology of Great Britain and 
Ireland [6, 7].
Perioperative IV lidocaine has well-established anti-
inflammatory and opioid-sparing analgesic properties 
[8–10]. There are also data to suggest a beneficial effect on 
return of GI function following abdominal surgery. How-
ever, interpretation of the existing literature is challenging, 
as it includes a variety of operations, access techniques and 
perioperative management protocols [11, 12]. Furthermore, 
despite the existence of validated consensus-derived com-
posite endpoint definitions of return of GI function (GI-2, 
GI-3) [2, 13, 14], many studies of perioperative IV lidocaine 
report a variety of sub-optimal univariate endpoints to meas-
ure GI recovery.
This study updates existing meta-analyses of periopera-
tive IV lidocaine by inclusion of new data and seeks to limit 
study heterogeneity by focusing on return of GI function 
following colorectal surgery.
Materials and methods
Literature search
The study was placed prospectively on the International Pro-
spective Register of Systematic Reviews (PROSPERO) reg-
ister [CRD42016049847]. A comprehensive search of Ovid 
Medline, PubMed, Embase, Cochrane library, and clinical-
trials.org was completed on 5th September 2018. A manual 
search of reference lists was also performed. The following 
search strategy was used: (colorectal surgery OR colectomy 
OR colon OR colonic OR bowel) AND (intravenous lido-
caine OR intravenous lignocaine OR lidocaine infusion OR 
lignocaine infusion OR IV lidocaine OR IV lignocaine OR 
I.V lidocaine).
Inclusion criteria
Randomized controlled trials (RCTs), human adults 
[> 16 years], open or laparoscopic colorectal resectional 
surgery.
Exclusion criteria
Non-colorectal surgery, non-placebo comparator, children, 
non-general anaesthetic, and pharmacokinetic studies.
Intervention and comparator
Intravenous lidocaine administered perioperatively was com-
pared to placebo (0.9% saline infusion) as part of a multi-
modal perioperative analgesic regimen.
Data extraction
Full-text randomized control trials meeting inclusion criteria 
were reviewed by two independent researchers (EK/CC). A 
proforma was used to extract relevant information: data pre-
sented as mean and standard deviation were extracted directly, 
whereas non-parametric results (median and interquartile 
range) were converted using previously described techniques. 
For skewed data, the median was used instead of the mean 
[15].
Primary outcome
Since none of the included studies reported the validated GI-2 
or GI-3 definitions of GI function, the primary outcome was 
time (hours) to first bowel movement (various phrases “bowel 
function”, “defecation”, and “bowel motion” were used in the 
included studies and we have assumed them to mean the same 
thing, i.e., defecation).
Secondary outcomes
Return of GI function
• Time to first passage of flatus (hours).
• Time to toleration of diet (hours).
• Incidence of postoperative ileus.
• Incidence of nausea and vomiting.
Pain
• Numerical pain score at rest at 24 h (score 0–10, 0 = no 
pain, 10 worst imaginable pain, alternative methods con-
verted to 0–10 range).
• Numerical pain score on movement at 24 h (0–10 as 
above).
• Opioid consumption over first 24 h after surgery (milli-
grams and morphine equivalent doses).
• Total opioid consumption (milligrams).
Other
• Length of stay (hours).
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Subgroup analyses
A predefined subgroup analysis was performed for open and 
laparoscopic surgery.
Bias and quality assessment
Overall quality and potential bias were assessed using a 
previously described 15-point scale adapted from criteria 
described by Chalmers and Jadad, with a threshold score 
of ≥ 12 for high quality (Table 1) [16, 17]. A sensitivity 
analysis was conducted for the primary endpoint by exclud-
ing each study.
Statistical analysis
Data were analyzed using the mean weighted difference 
(WMD) and pooled odds ratios for continuous variables and 
dichotomous data, respectively. A random effects model was 
selected on the basis of radial plots of the primary outcome. 
Statistical significance was set at p < 0.05. Heterogeneity 
was classified as low (< 33%), medium (33–66), or high 
(> 66%) using I2 estimated using the restricted maximum 
likelihood estimator function. Data were analyzed using the 
metafor package in R (version 3.4.2, R statistical program-
ming, Vienna) [26].
Results
Nine RCTs were identified by the literature search strategy 
detailed in the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) flow diagram in 
Fig. 1, with a total of 405 patients. All results and figures 
are presented in supplementary data.
Primary outcome: time to first bowel movement
IV lidocaine was associated with a significantly reduced 
time to first bowel movement (Fig. 2) in pooled analysis 
compared with placebo (seven studies, 325 patients, WMD 
− 9.54 h, 95%CI 18.72 to − 0.36, p = 0.04). In subgroup 
analyses, IV lidocaine reduced time to first bowel movement 
in both open (three studies, 139 patients; WMD − 14.87 h, 
95%CI 25.92 to − 3.81, p = 0.008) and laparoscopic surgery 
(four studies, 186 patients; WMD − 12.1 h, 95%CI 23.6 to 
− 0.59, p = 0.04).
Secondary outcomes
Time to first passage of flatus
Intravenous lidocaine did not significantly improve time 
to first passage of flatus in pooled analysis (8 studies, 345 
patients; WMD − 3.42 h, 95%CI 10.41–3.58, p = 0.339). 
There was a significant decrease in the time to first passage 
of flatus in the open subgroup (five studies, 229 patients; 
WMD − 7.07 h, 95%CI 13.58 to − 0.57, p = 0.033) but not 
the laparoscopic subgroup (three studies, 126 patients; 
WMD − 4.58 h, 95%CI − 18.22 to 9.07, p = 0.511).
Time to resumption of diet
Only three studies reported this endpoint. IV lidocaine 
did not significantly hasten the time to toleration of diet 
in pooled analysis (three studies, 188 patients; WMD—
10.93 h, 95%CI − 23.03 to 1.17, p = 0.077). IV lidocaine was 
associated with a shorter time to toleration of diet compared 
with placebo only in the laparoscopic subgroup (two stud-
ies, 128 patients; WMD − 5.97 h, 95%CI − 6.88 to − 5.09, 
p < 0.001). However, this was heavily weighted by a single 
study. Furthermore, resumption of diet is a less objective 
measurement than return of bowel function, as it greatly 
varies by individual practice.
Nausea and vomiting
There was no significant difference in nausea and vomit-
ing events when comparing IV lidocaine with placebo in 
pooled analysis (five studies, 271 patients, OR 0.54, 95%CI 
0.21–1.41, p = 0.150). There was no significant difference in 
the laparoscopic and open subgroups.
Incidence of postoperative ileus
In pooled analysis, there was a significant reduction in the 
incidence of postoperative ileus in the IV lidocaine group 
(five studies, 256 patients, OR 0.32, 95%CI 0.15–0.71, 
p = 0.02). No differences in the incidence of postoperative 
ileus were seen in subgroup analyses.
Pain score at rest at 24 h
Intravenous lidocaine was associated with lower pain scores 
at rest at 24 h compared with placebo (seven studies, 280 
patients, WMD − 0.72, 95%CI − 1.31 to − 0.13, p = 0.020). 
This benefit was seen in the open subgroup (four studies, 159 
patients, WMD − 0.36, 95%CI − 0.66 to − 0.06, p = 0.02). 
There was no significant difference in the laparoscopic 
subgroup.
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Pain score on movement at 24 h
Intravenous lidocaine was associated with lower pain scores 
on movement at 24 h compared with placebo (four studies, 
133 patients, WMD − 1.02, CI − 1.89 to − 0.14, p = 0.020). 
This effect was seen in the laparoscopic (two studies, WMD 
− 1.70, 95%CI − 2.18 to − 1.22, p < 0.0001) but not the open 
subgroup (two studies, 80 patients, WMD − 0.38, 95%CI 
− 1.06 to 0.31, p = 0.28).
Opioid consumption during first 24 h after operation
There was no difference in opioid consumption in the first 
24 h after operation in pooled or subgroup analyses (pooled 
analysis five studies, 205 patients; WMD − 4.24 mg, 95%CI 
− 9.86 to 1.38, p = 0.14).
Total opioid consumption
There was no significant difference in total opioid consump-
tion in pooled or subgroup analyses (pooled analysis seven 
studies, 305 patients; WMD − 5.82 mg, 95%CI − 22.32 to 
10.67, p = 0.49).
Length of stay
Intravenous lidocaine was associated with shorter length of 
stay in pooled analysis (seven studies, 347 patients; WMD 
− 17.84 h, 95%CI − 32.95 to − 2.74 h, p = 0.020). This was 
the case in both laparoscopic (three studies, 168 patients; 
WMD − 23.04 h, 95%CI − 32.52 to − 13.56 h, p < 0.0001) 
and open subgroups (four studies, 179 patients; WMD 
− 19.62 h, 95% CI − 36.66 to − 2.59 h, p = 0.020).
Forest plots for secondary outcomes are shown in Sup-
plementary data 1.
Discussion
Previous meta-analyses of perioperative IV lidocaine have 
included a diverse range of operative procedures and focused 
on opioid analgesic consumption and pain scores [27, 28]. 
This meta-analysis examined the effect of IV lidocaine on 
return of GI function after major colorectal surgery, a critical 
determinant of recovery and discharge from hospital for this 
patient group. Time to first bowel movement was reduced by 
approximately 15 h in open and 12 h in laparoscopic surgery. 
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Consistent with this finding was a substantially reduced risk 
of postoperative ileus (OR 0.32), reduced early pain scores, 
and reduced length of hospital stay of approximately 18 h 
(95% CI − 2.74 to − 32.95 h). If these findings were repli-
cated in routine practice, perioperative IV lidocaine could 
hasten recovery, reduce postoperative ileus, and reduce 
length of stay for a significant proportion of patients. Given 
that colectomy is a common operation undertaken in every 
acute hospital in the western world, considerable cost sav-
ings could be achieved in reduced bed occupancy from this 
straightforward and inexpensive intervention. Although this 
analysis did not specifically study the safety of IV lidocaine, 
it is a familiar drug and the previous reviews suggest a low 
incidence of IV lidocaine-associated toxicity [29].
The mechanism of action of IV lidocaine in this set-
ting remains uncertain. Pain scores were lower with IV 
lidocaine, but opioid consumption was not significantly 
different, suggesting that the faster return of gut function 
was not solely due to opiate sparing [30, 31]. IV lidocaine 
has a variety of analgesic and anti-inflammatory effects 
mediated through sodium channel receptors (recently sum-
marized in detail [32]) and is known to reduce postopera-
tive serum cytokine levels, suggesting that it acts centrally 
and peripherally to blunt the pro-inflammatory response to 
surgery [18, 33]. Postoperative ileus is multifactorial, and 
IV lidocaine probably acts via more than one mechanism.
Our study aimed to highlight potential benefits of 
perioperative IV lidocaine to colorectal surgeons, but has 
several limitations and its results need to be interpreted 
carefully. No study reported the consensus-derived, vali-
dated GI-2 or GI-3 composite endpoints of GI function and 
not all univariate endpoints were reported by all studies 
(for example, time to resumption of diet, integral to the 
GI2/GI-3 endpoint, was reported by only three studies). 
Although dose was consistent between studies (1–2 mg/
kg/h), duration of infusion was not: most studies used 
24 h, but ranged from operation only [22, 24] to 5 days 
(Elhafz et al. [18]). The latter study is, therefore, a meth-
odological outlier, elimination of which in sensitivity anal-
ysis (Supplementary data 2) leads to a loss of statistical 
significance for the laparoscopic subgroup for the primary 
endpoint. This sensitivity analysis shows that our results 
are susceptible to removal of individual studies, reflecting 
study heterogeneity and the small total sample size, and is 
another reason for cautious interpretation.
Currently, the ‘correct’ duration of infusion is unknown. 
The intraoperative period is probably the most important; 
thereafter, continuation of the infusion depends on avail-
ability of cardiac monitoring beyond the theatre suite, 
which may be dictated by local resources. Plasma accu-
mulation, and hence risk of toxicity, is unlikely with less 
than 24 h continuous infusion [32]. The authors’ local 
practice is a 12-h infusion, and the UK ALLEGRO trial 
Fig. 2  Forest plot of time from operation to first bowel movement
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of perioperative IV lidocaine will compare outcomes from 
6-h and 12-h infusion [34].
Finally, few studies reported a perioperative protocol 
consistent with modern enhanced recovery principles. 
Notably, those that did had short lengths of stay (median 
3–4 days) and showed a clear benefit from IV lidocaine 
[19, 21]. In contrast, where enhanced recovery protocols 
were not used/reported and length of stay was longer 
(median 8–9 days), no benefit was shown [20, 25]. This 
suggests that IV lidocaine exerted the greatest benefit on 
early recovery and was most effective within a modern 
patient care protocol; conversely, where length of stay was 
long (outdated care pathways, complex case mix, or high 
complication rates), a benefit was more difficult to detect.
Conclusions
Although this analysis reduces heterogeneity by includ-
ing colorectal surgery only, most studies were small, set in 
contrasting perioperative care protocols and reported sub-
optimal endpoints to assess postoperative GI function. Nev-
ertheless, an intriguing signal of benefit from IV lidocaine 
was seen consistently across the reported outcomes, suggest-
ing that perioperative IV lidocaine could have a clinically 
meaningful effect on return of GI function, and hence, length 
of stay after colorectal surgery. IV lidocaine is inexpensive, 
straightforward to administer within existing evidence-based 
perioperative care protocols, and appears safe. Large-scale 
pragmatic effectiveness trials embedded within modern 
perioperative protocols are warranted to confirm or refute 
these findings and optimize dose and duration of infusion.
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